Whalesbook
### Strategic Pivot to Value
The Indian pharmaceutical and medical device industries are fundamentally recalibrating their growth engines, moving decisively from a volume-centric model to one prioritizing value and sophisticated innovation. This strategic recalibration, as highlighted in the Economic Survey 2025-26, emphasizes complex generics, biosimilars, and novel research and development to ascend the global value chain. The sector's annual turnover reached an estimated ₹4.72 lakh crore in FY25, with exports growing at a compound annual growth rate (CAGR) of 7% over the past decade. Over half of these exports are directed to highly regulated markets like the US and Europe, underscoring a commitment to stringent quality standards. Furthermore, the recent conclusion of the India-European Union Free Trade Agreement (FTA) is poised to significantly enhance market access to the EU's $572.3 billion pharmaceutical and medical devices market by eliminating tariffs on key Indian exports. This historic deal is expected to foster faster growth in high-value segments and reinforce India's position as a reliable global healthcare partner [24, 29, 34, 40].
### Medical Devices Ascend
Parallel to pharmaceuticals, India's medical devices sector is demonstrating substantial momentum. Exports in this segment grew from USD 2.5 billion in FY21 to USD 4.1 billion in FY25. To further reduce import dependence and bolster international market access, the adoption of advanced manufacturing technologies such as AI and 3D printing is deemed critical. The industry is increasingly manufacturing high-end equipment, including MRI and CT scanners, linear accelerators, cardiac stents, and ventilators. India's medical devices market was valued at approximately USD 16.97 billion in 2025 and is projected to reach USD 26.66 billion by 2031, at a CAGR of 7.82% [14]. Strategic government initiatives and private sector investments are central to this trajectory, with the Production-Linked Incentive (PLI) scheme attracting significant domestic manufacturing of advanced equipment [9, 16, 21].
### Global Competitiveness & Challenges
Despite these strides, the sector faces significant hurdles. A recent analysis indicates that Indian pharmaceutical firms lag behind global counterparts in R&D intensity, with global companies investing approximately three times more [22]. While Indian companies show better performance in patents-to-revenue ratios, overall innovation output requires enhancement to fully capitalize on the value-driven strategy. Concurrently, the Nifty Pharma index, representing the broader sector, exhibits technical weakness. As of January 28, 2026, the index was trading around 21,581.85, closer to its 52-week low of 19,121.1 than its high of 23,492.55 [12]. Technical indicators signal a "Strong Sell," contrasting with the generally stable outlook projected by rating agencies like ICRA, which forecasts revenue growth of 9-11% for FY2026 [36]. The Indian equity market has also endured an 18-month period of stagnation with significant stock drawdowns, suggesting a cautious investor sentiment that may temper the immediate impact of fundamental sector improvements [27].
### Outlook and Analyst Views
The long-term outlook for India's pharmaceutical and medical device sectors remains positive, driven by the strategic shift towards high-value products, expanding export markets, and supportive policy frameworks like the India-EU FTA. The projected growth in the medical devices market and the increasing global demand for biosimilars further bolster these prospects. However, sustained success hinges on bridging the R&D gap with global competitors and navigating current market technicals. Increased investment in research and development, alongside a focus on talent development in areas like AI and bioinformatics, will be crucial for India to fully realize its ambition of becoming a leading global hub for advanced healthcare manufacturing and innovation.